The Rare Disease Company Coalition (RDCC) released a new one-pager on how most-favored nation (MFN) pricing policies could undermine rare disease innovation and limit patient access. With 95% of rare diseases lacking FDA-approved treatments, companies already face lengthy and expensive development challenges. MFN policies, which tie U.S. drug prices to prices abroad, risk creating delays and access barriers seen in other countries, where many orphan drugs never reach patients. RDCC urges policymakers to protect innovation and access by supporting an orphan drug exemption from MFN policies.
Read more in RDCC’s one-pager below.
.